Fig. 4: Benchmarking of ALFQ-adjuvanted junctional+minor repeat and major repeat TMV constructs against RTS,S/AS01 in the Pb-PfCSP in vivo liver burden model (JHU mouse study 1).

A Schematic of study outline. C57Bl/6 mice (n = 5) were vaccinated with ALFQ-adjuvanted T5, T20 (0.2-, 1, or 2.5 µg dose), T51 (1 or 2.5 µg dose), or RTS,S/AS01 (0.05 or 5 µg dose). Sera was collected at 2WP3, and mice were challenged via intravenous administration of 2000 Pb-PfCSP transgenic sporozoites. The liver burden reduction was assessed 42 hours post-challenge. B NANPx6 geometric mean ELISA titers with 95% confidence intervals of T5-, T20-, and T51-vaccinated sera for each dose group as compared to RTS,S/AS01. C Geometric mean percentage liver burden inhibition with 95% confidence intervals of T5-, T20-, and T51-vaccinated mice sera for each dose group as compared to RTS,S/AS01 (luminescence signal compared to naïve controls). D Inhibition of parasite burden vs. 2A10 equivalents for individual mice. Points are colored according to the dose group schema used in (B) and (C). E Modeled liver burden (total flux) vs. antibody concentration (mAb 2A10 equivalents). The black solid line represents historic RTS,S/AS01 vaccine performance in the JHU model, and the dashed blue line represents a theoretical 3x improvement over RTS,S/AS01. F ILSDA results for select ALFQ-adjuvanted vaccine groups conducted at 1:10, 1:50, and 1:150 serum diluions. Mean values with 95% confidence intervals are plotted.